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The authors wanted to find out to what extent patients followed for stable coronary artery disease (CAD) and patients followed after an acute coronary syndrome (ACS) event achieve the guideline-based treatment goals for low-density lipoprotein cholesterol (LDL-C). The conclusion of the study is that low numbers of patients with CAD in Europe reach their recommended LDL-C target. The authors correctly point out that it is important that such patients achieve the guideline-based treatment goals for LDL-C (or even lower), because several high-quality intervention studies have shown that the lower the treated LDL-C, the lower the risk of major cardiovascular events, such as non-fatal acute myocardial infarctions, non-fatal strokes or coronary revascularizations, whereas overall mortality is not affected. [2] [3] [4] Nevertheless, there are some issues in the paper that attract attention and could be discussed further.
The authors mention that they are dealing with very high-risk patients, but they did not initially define what they mean by very high risk and they did not initially discuss whether further reduction of LDL-C in their study population will in fact save lives or how many major cardiovascular events will be avoided by further LDL-C lowering. I am certainly not saying that it is not important to prevent major cardiovascular events, particularly stroke, in patients with CAD, but I think we sometimes forget that patients with CAD do quite well these days, so maybe the term 'very high risk' should be downgraded to 'high risk'. For example, in a Danish single centre cohort study, including 2804 consecutive patients with ST-segment elevation myocardial infarction (STEMI) (age 63 AE 13 years, 72% males) treated with primary percutaneous coronary intervention (PCI) and followed up for a median of 4.7 years, the patients who survived the first month after their primary PCI-treated STEMI had an overall good prognosis with a < 1.5% annual risk of cardiac death. 5 In fact, non-cardiac causes, such as cancers and pulmonary diseases, were responsible for most of the later deaths in these patients. 5 In another Danish PCI cohort study, the SORT OUT II study, including 2098 patients (age 64 AE 11 years, 75% males) treated with PCI for STEMI, non-STEMI or unstable angina pectoris or stable angina, cardiac death occurred at around 1% per year during the 10-year follow-up period and again most patients died of noncardiac causes, such as cancers and pulmonary diseases. 6 So, in my daily clinical work, I tell stable patients with ACS that due to the enormous improvements in the treatment of CAD during the last 20 years, they will probably die of something other than heart disease, although I of course cannot give a 100% guarantee, and it is my impression that they like this information. In this perspective, the latest published large randomized clinical studies on further lipid lowering therapy did not show any mortality benefit and, indeed, only modest benefit regarding CAD outcomes, with high numbers needed to treat to gain benefit. 3, 4 This issue is important, taking healthcare costs into account, when introducing new and very expensive lipid-lowering therapies.
A further point to discuss is the low mean daily dosage of statins used by the patients in the study. Particularly, it is a surprise that the mean daily dosage of statins, normalized to atorvastatin potency, was only 22 AE 17 mg among the ACS patients at the beginning of the study. In fact, it is of interest why most ACS patients were not taking 80 mg of atorvastatin. In my country, after atorvastatin became generic in 2012, basically all patients with an ACS are started on 80 mg of atorvastatin during the index hospital admission, based on the results from the PROVE IT-TIMI 22 study published in 2004.
had an ACS event, an aggressive lipid-lowering strategy with 80 mg of atorvastatin provided greater protection against death or major cardiovascular events than did a standard regimen with 40 mg of pravastatin with an acceptable safety profile and similar discontinuation rates, taking all issues into account. 7 In the same way, based on the Treating to New Targets study, published in 2005, which showed that intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CAD provided significant clinical benefit beyond that provided by treatment with 10 mg of atorvastatin per day with an acceptable safety profile and only a slightly higher discontinuation rate due to treatment-related adverse events (7.2% and 5.3% (p < 0.001)), 2 we basically start all patients with stable CAD on 80 mg of atorvastatin, too. Accordingly, we rarely consider a treatto-target strategy in patients with CAD, as has been recommended previously, 8 but use a high dose-adapted statin treatment strategy. So, apparently in contrast to a strategy of up-titration of statin dosage in the countries participating in the DYSIS II Europe study, we prefer to prescribe the maximal dosage of atorvastatin right away, followed by watchful waiting in the ambulatory setting, and in the case of clinical and paraclinical adverse events, we then down-titrate the statin dosage. We think this is the best approach taking further cardiovascular prevention into consideration among patients with CAD after moving from using less effective statins, such as simvastatin and pravastatin, to using other, more effective, statins, for example atorvastatin and rosuvastatin, in secondary cardiovascular prevention; although, as also reported in the DYSIS II Europe study, 1 treating women with statins can be difficult due to side-effects. Therefore, to get lower LDL-C concentrations among patients with CAD in Europe and to get more patients with CAD in Europe to achieve their LDL-C treatment goals, I will recommend starting most patients with CAD in Europe on 80 mg of atorvastatin as soon as possible and then see what happens with respect to clinical and paraclinical adverse events. I think this measure in an effective and cost-efficient way will substantially reduce the number of new admissions for ACSs and the need for coronary revascularizations in Europe. In this context, I think it is fair to say that our high-intensity statin strategy to a large extent is supported by a recent Norwegian study that showed that moderate-or low-intensity statin therapy was a major determinant of unfavourable LDL-C control. 9 Further, because only a minority of those prescribed lipid-lowering drugs in the EUROASPIRE IV cross-sectional survey reached the LDL-C target of < 2.5 mmol/l, 10 it could be argued that even in primary prevention, a high-intensity statin strategy should be considered.
Nevertheless, I also think that it is important to tell the typical patients with CAD in Europe that if they do not smoke, overall eat a healthy diet, exercise and take their cardiovascular medications as prescribed, including high-intensity statin therapy, their prognosis regarding dying of heart disease has improved tremendously during the last 20 years, and they will probably die of something else. 5, 6 Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
